Silence Therapeutics September 2022 Forward-Looking Statements The information contained in this presentation is being supplied and communicated to you solely for your information and may not be reproduced, further distributed to any other person or published, in whole or in part, for any purpose. The distribution of this presentation in certain jurisdictions may be restricted by law, and persons into whose possession this presentation comes should inform themselves about, and observe, any such restrictions ...

Silence Therapeutics July 13, 2022 Forward-Looking Statements The information contained in this presentation is being supplied and communicated to you solely for your information and may not be reproduced, further distributed to any other person or published, in whole or in part, for any purpose. The distribution of this presentation in certain jurisdictions may be restricted by law, and persons into whose possession this presentation comes should inform themselves about, and observe, any such restrictions. ...

Silence Therapeutics plc (NASDAQ:SLN) Q4 2021 Earnings Conference Call March 17, 2022 8:00 AM ET Company Participants Gem Hopkins - Head of Investor Relations and Corporate Communications Craig Tooman - President and Chief Executive Officer Rhonda Hellums - Chief Financial Officer Giles Campion - Head of R&D Conference Call Participants Tom Shrader - BTIG Patrick Trucchio - H.C. Wainright Myles Minter - William Blair Operator Good day, ladies and gentlemen, and welcome to the Silence Therapeutics Full Year ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF ...

| --- | --- | |----------------------------------------------------------|-------| | | | | | | | | | | March 2022 Corporate Presentation Silence Therapeutics | | Forward-Looking Statements 2 The information contained in this presentation is being supplied and communicated to you solely for your information and may not be reproduced, further distributed to any other person or published, in whole or in part, for any purpose. The distribution of this presentation in certain jurisdictions may be restricted by l ...

Silence Therapeutics plc (NASDAQ:SLN) Q2 2021 Earnings Conference Call August 12, 2021 8:00 AM ET Company Participants Gem Hopkins - Head, Investor Relations and Corporate Communications Mark Rothera - President and CEO Craig Tooman - Chief Financial Officer Giles Campion - EVP, Head of R&D and CMO Conference Call Participants Thomas Shrader - BTIG Patrick Trucchio - H.C. Wainwright Myles Minter - William Blair Operator Good day, ladies and gentlemen and welcome to the Silence Therapeutics Interim Results 2 ...

| --- | --- | |-------|-------| | | | | | | Forward-Looking Statements 2 The information contained in this presentation is being supplied and communicated to you solely for your information and may not be reproduced, further distributed to any other person or published, in whole or in part, for any purpose. The distribution of this presentation in certain jurisdictions may be restricted by law, and persons into whose possession this presentation comes should inform themselves about, and observe, any such re ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF ...

Silence Therapeutics FY20 Results March 30, 2021 Forward-Looking Statements 2 The information contained in this presentation is being supplied and communicated to you solely for your information and may not be reproduced, further distributed to any other person or published, in whole or in part, for any purpose. The distribution of this presentation in certain jurisdictions may be restricted by law, and persons into whose possession this presentation comes should inform themselves about, and observe, any su ...

Silence Therapeutics plc (NASDAQ:SLN) Q4 2020 Results Earnings Conference Call March 30, 2021 8:00 AM ET Company Participants Gem Hopkins - Head, Investor Relations and Corporate Communications Mark Rothera - President and CEO Craig Tooman - Chief Financial Officer Dr. Giles Campion - Head, R&D and CMO Conference Call Participants Julian Harrison - BTIG Patrick Trucchio - H.C. Wainwright Miles Dixon - Peel Hunt Myles Minter - William Blair Operator Good day, ladies and gentlemen. And welcome to the Silence ...